Avidity Biosciences (RNA) Projected to Post Earnings on Thursday

Avidity Biosciences (NASDAQ:RNA) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.24) per share and revenue of $1.9820 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, February 23, 2026 at 7:00 AM ET.

Avidity Biosciences Trading Down 0.2%

Avidity Biosciences stock opened at $72.75 on Wednesday. Avidity Biosciences has a 12 month low of $21.51 and a 12 month high of $73.06. The business’s fifty day simple moving average is $72.52 and its two-hundred day simple moving average is $61.75. The company has a market capitalization of $11.26 billion, a price-to-earnings ratio of -17.40 and a beta of 0.93.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RNA. Chardan Capital reiterated a “neutral” rating and set a $72.00 price objective on shares of Avidity Biosciences in a research report on Tuesday, November 11th. Wolfe Research cut shares of Avidity Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Evercore set a $72.00 price target on shares of Avidity Biosciences in a research report on Thursday, December 18th. Loop Capital set a $72.00 price target on shares of Avidity Biosciences in a research note on Tuesday, October 28th. Finally, TD Cowen restated a “hold” rating on shares of Avidity Biosciences in a research note on Wednesday, November 12th. Eight research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Avidity Biosciences has an average rating of “Hold” and a consensus target price of $69.57.

Insider Buying and Selling

In other Avidity Biosciences news, insider Steven George Hughes sold 4,895 shares of the stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $72.45, for a total transaction of $354,642.75. Following the completion of the transaction, the insider owned 31,599 shares in the company, valued at $2,289,347.55. This trade represents a 13.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider W. Michael Flanagan sold 6,534 shares of Avidity Biosciences stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $72.45, for a total transaction of $473,388.30. Following the completion of the transaction, the insider directly owned 85,093 shares of the company’s stock, valued at $6,164,987.85. The trade was a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 58,407 shares of company stock valued at $4,226,448 in the last ninety days. Company insiders own 3.83% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. EFG International AG bought a new stake in shares of Avidity Biosciences during the 4th quarter worth approximately $33,000. Smartleaf Asset Management LLC increased its stake in Avidity Biosciences by 426.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 490 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 397 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of Avidity Biosciences during the fourth quarter worth $34,000. Comerica Bank boosted its stake in shares of Avidity Biosciences by 75.9% during the third quarter. Comerica Bank now owns 1,335 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 576 shares during the period. Finally, Osaic Holdings Inc. increased its stake in Avidity Biosciences by 1,659.1% in the 2nd quarter. Osaic Holdings Inc. now owns 1,636 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,543 shares during the period.

About Avidity Biosciences

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.